TSX: HSM     OTC: HSDT

Call us: +1 215-809-2018

newsBanner

Three Poster Presentations Featured at Medical Meetings

NEWTOWN, PA – June 28, 2017 – Helius Medical Technologies, Inc. (TSX: HSM and HSM.WT and OTCQB: HSDT) ("Helius" or the "Company")  announced today that new data has been and will be presented at several medical meetings in the United States and France in 2017. The data comes from research studies investigating the use of the Portable Neuromodulation Stimulator (PoNS) Therapy for the rehabilitation of symptoms in subjects with stroke and tinnitus. This research took place at the Tactile Communication and Neurorehabilitationition Laboratory (TCNL) at University of Wisconsin – Madison and the Pavlov Institute of Physiology, Russian Academy of Science in St. Petersburg, Russia.

A presentation on the rehabilitation of chronic symptoms caused by stroke, using PoNS Therapy, was presented by authors Yuri Danilov, Mitch Tyler and Dafna Paltin at the 12th World Congress on Brain Injury that took place in New Orleans in April 2017.

A presentation on the rehabilitation of emotion and speech symptoms caused by stroke, using the PoNS™ Therapy, was presented by authors Yuri Danilov, Mitch Tyler and Dafna Paltin at the American College of Sports Medicine Annual Meeting on May 31, 2017.

Later this month, results from research on Tinnitus suppression using PoNS Therapy and targeted auditory training programs will be presented by Yuri Danilov and co-authors at the International Federation of Oto-Rhino Laryngolocial Society World Congress in Paris on June 27, 2017.

“We continue to discover and investigate new and exciting potential uses for the PoNS Therapy. The latest results are very promising, but will require continued research to understand the physiological changes taking place and to improve the methodology of the intervention,” said study author and Research Director of TCNL, Dr. Yuri Danilov.

“We are delighted to see continued positive findings from our research partners at TCNL. We look forward to building on this research as we continue investigating new and exciting potential uses for the PoNS Therapy and continue helping those who suffer from neurological symptoms of disease or trauma,” said Philippe Deschamps, CEO of Helius.

About PoNS™ Therapy

The Portable Neuromodulation Stimulator (PoNS) is an investigational non-invasive device designed to deliver neurostimulation through the tongue. PoNS Therapy combines the use of the device with physical or cognitive therapy and is currently being evaluated in a multicenter clinical trial for the treatment of balance disorder for subjects with mild to moderate Traumatic Brain Injury.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a medical technology company focused on neurological wellness. Helius seeks to develop, license and acquire unique and non-invasive platform technologies that amplify the brain's ability to heal itself. For more information, please visit www.heliusmedical.com.

About TCNL

Founded in 1992, the Tactile Communication and Neurorehabilitation Laboratory (TCNL) is located at the University of Wisconsin in Madison. They are a research center that uses the experience of many different areas of science to study the theory and application of applied neuroplasticity, the brain's ability to reorganize in response to new information, needs, and pathways. The aim of their research is the development of solutions for sensory and motor disorders. Their center has three core areas that form the backbone of their research: neuromodulation, sensory substitution, and electrotactile stimulation. TCNL is administratively part of the UW-Madison Department of Kinesiology.

The Toronto Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Cautionary Disclaimer Statement:

Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws (“forward-looking statements”).

All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Such forward-looking statements include, among others, statements regarding the expected use of proceeds from the Private Placement and the business objectives of the Company.

Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions.

There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the necessity of conducting successful clinical testing to establish safety and effectiveness of the PoNS Therapy for human performance improvement, the requirement for regulatory approval for marketing for human performance improvement prior to the Company’s ability to commercialize the PoNS Therapy for such indications, and other risks detailed from time to time in the filings made by the Company with securities regulators.

The reader is cautioned that assumptions used in the preparation of any forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking statement. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Risks and uncertainties about the Company’s business are more fully discussed in the Company’s Transition Report on Form 10-K for the period ended December 31, 2016, which has been filed with the United States Securities and Exchange Commission and the Canadian securities regulators and which can be obtained from either at www.sec.gov or www.sedar.com, and the Company’s other filings with the SEC and Canadian securities regulators from time to time.

The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.

CONTACT

Investor Relations: Josh Berg
415-205-7891
info@heliusmedical.com

Media Contact: Becky Kern
914-772-2310
bkern@heliusmedical.com